결핵균의 Rv0577 단백질을 이용한 수지상 세포의 성숙방법
    13.
    发明公开
    결핵균의 Rv0577 단백질을 이용한 수지상 세포의 성숙방법 有权
    使用M.TUBERCULOSIS RV0577的感染细胞的成熟方法

    公开(公告)号:KR1020130012455A

    公开(公告)日:2013-02-04

    申请号:KR1020110073680

    申请日:2011-07-25

    Abstract: PURPOSE: A composition which contains RV0577 and induces dendritic cell maturation is provided to effectively activate immune response. CONSTITUTION: A composition which induces dendritic cell matutaton contains 1-10 ug/ml of RV0577 protein as an active ingredient. The protein is derived from M-tuberculosis. RV0577 protein enhances the expression of CD(Cluster of Differentiation)80, CD86, MHC(Major Histocompatibility Complex)-class I, II in a dendritic cell. A method for inducing maturation of the immature dendritic cells comprises: a step of sorting the immature dendritic cells; and a step of treating 1-10 ug/ml of RV0577 protein to the sorted immature dendritic cells.

    Abstract translation: 目的:提供含有RV0577并诱导树突状细胞成熟的组合物以有效激活免疫应答。 构成:诱导树突状细胞成熟的组合物含有1-10ug / ml的RV0577蛋白作为活性成分。 该蛋白质来源于结核分枝杆菌。 树突状细胞中RV0577蛋白增强CD(分化簇)80,CD86,MHC(主要组织相容性复合物) - I,II型的表达。 诱导未成熟树突状细胞成熟的方法包括:分选未成熟树突状细胞的步骤; 以及将1-10ug / ml的RV0577蛋白质处理至分选的未成熟树突状细胞的步骤。

    마이코박테리움 파라투버큘로시스를 포함한 염증성 장질환의 예방 및 치료용 백신
    14.
    发明公开
    마이코박테리움 파라투버큘로시스를 포함한 염증성 장질환의 예방 및 치료용 백신 有权
    用于预防和治疗包含MYCOBACTERIUM PARATUBERCULOSIS的炎症性皮肤病的疫苗

    公开(公告)号:KR1020120082529A

    公开(公告)日:2012-07-24

    申请号:KR1020110003830

    申请日:2011-01-14

    CPC classification number: A61K39/04 A61K39/39 Y10S514/925

    Abstract: PURPOSE: A vaccine containing Mycobacterium paratuberculosis and a vaccine composition containing the same are provided to effectively prevent inflammatory bowel disease. CONSTITUTION: A vaccine for preventing and treating inflammatory bowel disease contains Mycobacterium paratuberculosis as an active ingredient. Mycobacterium paratuberculosis is live bacteria or killed bacteria. The inflammatory bowel disease includes ulcerative colitis or Crohn's disease. A vaccine composition for preventing and treating inflammatory bowel disease contains the vaccine and pharmaceutically acceptable carrier or immunoadjuvant.

    Abstract translation: 目的:提供含有副结核分枝杆菌的疫苗和含有该病毒的疫苗组合物,以有效预防炎症性肠病。 构成:预防和治疗炎症性肠病的疫苗含有副结核分枝杆菌作为活性成分。 副结核分枝杆菌是活细菌或杀死细菌。 炎症性肠病包括溃疡性结肠炎或克罗恩氏病。 用于预防和治疗炎性肠病的疫苗组合物含有疫苗和药学上可接受的载体或免疫佐剂。

    마이코박테리움 압세수스의 MAB0981c 단백질을 이용한 수지상 세포의 성숙방법
    17.
    发明公开
    마이코박테리움 압세수스의 MAB0981c 단백질을 이용한 수지상 세포의 성숙방법 有权
    使用分枝杆菌MAB0981c树突状细胞的成熟方法

    公开(公告)号:KR1020120129442A

    公开(公告)日:2012-11-28

    申请号:KR1020110047697

    申请日:2011-05-20

    Abstract: PURPOSE: A maturing method of dendritic cell using MAB 0981c protein of Mycobacterium abscessus is provided to effectively promotes immune reaction of body. CONSTITUTION: A maturing method of dendritic cell contains MAB 0981c protein of Mycobacterium abscessus as an active ingredient. The MAB0981c protein is Mycobacterium abscessus originated protein. 1 micro gram/ml-10 micro grams/ml of the MAB0981c protein is included. A mature dendritic cell is increases the production of interferon-gamma (IFN-γ) inside CD(cluster of differentiation) 4+ and CD8+ thymusdependentlymphocyte. The mature dendritic cell is dendritic cell with an increased expression of chemokine receptor 7. The mature dendritic cell is dendritic cell with improved mobility. The process density of MAB0981c is 1 micro gram/ml-10micro grams/ml.

    Abstract translation: 目的:提供使用脓肿分枝杆菌MAB 0981c蛋白的树突状细胞成熟方法,有效促进人体免疫反应。 构成:树突状细胞的成熟方法含有脓肿分枝杆菌的MAB 0981c蛋白作为活性成分。 MAB0981c蛋白是脓肿分枝杆菌起源蛋白。 包括1微克/毫升-10微克/毫升的MAB0981c蛋白。 成熟的树突细胞增加CD(分化簇)4+和CD8 +胸腺依赖性淋巴细胞内的干扰素-γ(IFN-γ)的产生。 成熟树突状细胞是趋化因子受体7表达增加的树突状细胞。成熟树突状细胞是具有改善的移动性的树突状细胞。 MAB0981c的工艺密度为1微克/毫升-10微克/毫升。

Patent Agency Ranking